Prandin

Quick links to important sections

Prandin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prandin

Property Description
Active ingredient Repaglinide
Form Oral Tablet
Pharmacological class Meglitinide Analog, Non-sulfonylurea Secretagogue
Common use Management of Type 2 Diabetes Mellitus
Origin Synthetic Compound

What Type of Medicine is Prandin?

Prandin is a prescription-only medication containing the active pharmaceutical ingredient Repaglinide, which is classified as an oral antihyperglycemic agent used for managing elevated blood sugar levels associated with Type 2 diabetes mellitus. Repaglinide belongs to the pharmacological group known as the meglitinide analogs, which are agents designed to promote the secretion of insulin. Clinically recognized for its rapid effect, the drug is formulated and supplied as an oral tablet formulation. Repaglinide is a synthetic compound and is chemically distinct from older secretagogue drugs like sulfonylureas. Its primary purpose is to serve as an essential component of the treatment plan for adults who require assistance controlling their blood glucose levels, often used to manage blood sugar when diet and exercise alone are insufficient.


Repaglinide: An Oral, Mealtime Glucose Regulator

The mechanism of Repaglinide positions it to function as a rapid-acting insulin secretagogue, focusing its therapeutic effect precisely around mealtimes. This single-active ingredient product is designed to work quickly by directly acting on the pancreatic beta cells, which helps to stimulate insulin release from the pancreas. Repaglinide is characterized by rapid absorption and a short half-life, making it suitable for pre-meal dosing. This differentiating feature is central to its utility as a mealtime glucose regulator. This specific and temporary pulse of insulin is effective for processing incoming carbohydrates and mitigating the rapid rise in blood sugar that typically follows food consumption, thereby efficiently reducing postprandial blood glucose spikes, which is its core benefit in the overall management of Type 2 diabetes mellitus.

What side effects are possible with Prandin?

Possible Side Effects and Safety Information

The safety profile of Prandin (Repaglinide) is based on classifications documented by official government regulatory authorities. The most frequently occurring adverse reaction is hypoglycemia (low blood sugar), which is classified as Very Common (occurring in 1 out of 10 people or more) in regulatory documents. This risk is inherent to the drug’s action as an insulin secretagogue.


Adverse reactions are formally grouped by the body system affected. Common (ge 1/100 to < 1/10) adverse events documented in the safety information include Headache, Upper Respiratory Infection, and Gastrointestinal Disorders such as nausea, diarrhea, vomiting, and constipation. Musculoskeletal effects like arthralgia and back pain are also classified as common.


Serious Adverse Reactions highlighted in official labeling include the potential for Severe Hepatic Dysfunction (jaundice, hepatitis) and cases of Pancreatitis reported through postmarketing surveillance. Severe systemic allergic reactions (Hypersensitivity), including anaphylactoid reactions and severe skin reactions like Stevens-Johnson Syndrome, are also officially documented.


Safety Considerations and Restrictions

Specific constraints are placed on the use of Repaglinide. It is contraindicated in patients with severe hepatic function disorder due to the increased risk of severe hypoglycemia. The medication is also contraindicated in individuals with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. Furthermore, its use is not recommended in pediatric patients or in older adults over 75 years of age, as safety and effectiveness have not been established in these populations. Safety documents note that temporary visual disturbances may occur, often at the initiation of treatment, due to changes in blood glucose levels.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official overdose information for Prandin (Repaglinide), strictly based on governmental regulatory documents.


Overdose Scope and Clinical Manifestations

Domain Official Regulatory Statement
Documented Overdose Presentations The primary presentation of an overdose is hypoglycemia (low blood sugar), which may manifest as cold sweats, confusion, fast heartbeat, or slurred speech [Source 1.2, 1.3].
Physiological Systems Affected The Metabolic (hypoglycemia) and Neurological systems (seizures, coma) are the key systems affected according to regulatory documents [Source 1.3, 2.7].
Population-specific Overdose Notes There is an increased risk of severe or prolonged hypoglycemia in patients with severe renal impairment due to reduced drug clearance [Source 1.3].
Severity Classification Overdose-induced hypoglycemia is officially classified as potentially severe and life-threatening [Source 1.3].

Required Emergency Actions and Management

Action Domain Official Regulatory Statement
Emergency-response statements Seek immediate medical attention and/or contact a Poison Control Center immediately when an overdose is suspected [Source 1.4].
When immediate help is required Immediate help is required for severe hypoglycemia, especially if accompanied by seizures, loss of consciousness, or coma [Source 2.7].
Official Supportive Management Severe hypoglycemia mandates the administration of intravenous glucose [Source 2.7]. For mild cases, oral glucose or sugar intake is the required supportive treatment [Source 1.4].
Monitoring Requirements Hospital monitoring for at least 24 hours is officially recommended due to the risk of recurrent or prolonged hypoglycemia [Source 3.6].

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by the central risk of metabolic collapse leading to severe neurological complications [Source 1.3, 2.7]. This profile mandates an immediate emergency response, including urgent glucose administration and extended hospital observation, as the required actions to manage the documented toxicity [Source 2.7, 3.6].

Therapeutic Uses of Prandin

Main Uses of Prandin

Prandin, known by the generic name repaglinide, is an oral medication used to help manage blood sugar levels in adults with type 2 diabetes mellitus. It belongs to a class of drugs called meglitinides, which are designed to stimulate the pancreas to release insulin more quickly after a meal.

This medication is specifically indicated for use as an adjunct to diet and exercise. It is intended for individuals whose blood sugar remains high despite lifestyle modifications. It may be prescribed as a monotherapy or in combination with other glucose-lowering agents, such as metformin or thiazolidinediones, when a single medication does not provide sufficient glycemic control.

How It Works

The primary function of Prandin is to address postprandial glucose—the rise in blood sugar that occurs after eating. In type 2 diabetes, the body may not produce enough insulin at the right time to process the glucose from food. By triggering a brief, rapid release of insulin from the pancreatic beta cells, the medication helps the body move sugar from the bloodstream into the cells, where it can be used for energy.

Benefits in Diabetes Management

Effective management of type 2 diabetes with medications like Prandin offers several clinical benefits focused on long-term health and stability:

  • Glycemic Control: By reducing peaks in blood sugar after meals, the medication helps lower the overall hemoglobin A1c (HbA1c) level, which is a measure of average blood sugar over time.
  • Targeted Insulin Delivery: Because its action is relatively short-lived and synchronized with meal times, it mimics the natural insulin response of the body more closely than some long-acting medications.
  • Flexibility: It allows for a management approach that is timed specifically to nutritional intake, addressing the immediate metabolic needs of the body during digestion.

Maintaining blood sugar within a target range is a fundamental goal in the management of type 2 diabetes to help reduce the risk of future health complications associated with chronic hyperglycemia.

Eligibility and Restrictions for Use

Eligibility for Prandin (Repaglinide) is strictly defined by regulatory authorities and is limited to specific patient populations for the management of Type 2 Diabetes Mellitus. Adults with Type 2 Diabetes are the approved population.


Contraindicated Populations Official Regulatory Status
Type 1 diabetes mellitus or diabetic ketoacidosis Absolute Contraindication
Severe hepatic function disorder (Severe liver disease) Absolute Contraindication (EMA)
Concomitant use of gemfibrozil Absolute Contraindication
Known hypersensitivity to repaglinide or excipients Absolute Contraindication

Specific Population Restrictions Official Regulatory Status
Pediatric patients (under 18 years) Safety and efficacy not established; not recommended
Pregnancy and Lactation Avoid use/Use not recommended (lack of data)
Severe renal impairment (CrCl 20-40 mL/min) Use requires careful titration and a lower starting dose

Prandin is exclusively indicated as an adjunct to diet and exercise for glycemic control in the adult population with Type 2 Diabetes Mellitus. Use is prohibited in patients with Type 1 Diabetes or acute metabolic conditions like ketoacidosis, and those taking the lipid-lowering agent gemfibrozil. Furthermore, the medicine is not recommended for children due to insufficient data, nor is it advised during pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Restrictions and Contraindications

Co-administration of Repaglinide with the medicinal product Gemfibrozil is formally contraindicated. This prohibition is established because Gemfibrozil significantly increases Repaglinide's plasma exposure, escalating the risk of severe hypoglycemia. Furthermore, Repaglinide is not indicated for use in combination with NPH-insulin due to observed adverse events in trials.


Exposure-Modifying Interactions

Repaglinide's interaction profile is significantly determined by its metabolism through the CYP2C8 and CYP3A4 enzymes, as well as its transport via the OATP1B1 uptake protein. Inhibitors of these pathways can lead to an increase in drug concentration (AUC and Cmax).

Specifically, co-administration with the CYP2C8 inhibitor Clopidogrel requires the Repaglinide total daily dose to be limited to a maximum of 4 mg. Similarly, when co-administered with Cyclosporine, the total daily dose must not exceed 6 mg. Conversely, strong enzyme inducers like Rifampin (Rifampicin) are documented to decrease Repaglinide exposure, which may alter its expected effect.


Pharmacodynamic Effects and Substance Interactions

Certain medicinal product classes, including Non-selective Beta Blocking Substances, Monoamine Oxidase Inhibitors (MAOI), and ACE Inhibitors, are officially documented to potentially cause pharmacodynamic augmentation, leading to an enhanced or prolonged glucose-lowering effect. A pharmacokinetic interaction also occurs with food, which is documented to decrease the peak plasma concentration of Repaglinide. For patients with severe hepatic function disorder, Repaglinide is formally contraindicated due to the high risk of drug accumulation.

Mechanism of Action

Molecular Mechanism of Repaglinide

The mechanism of Repaglinide is initiated by its selective action on the beta-cells of the pancreas. Its primary target is the Sulfonylurea Receptor 1 ( SUR1) subunit of the ATP-dependent potassium channel ( K ATP) complex on the cell membrane. By physically blocking this channel, Repaglinide halts the efflux of potassium ions ( K^+) and rapidly causes the beta-cell membrane to depolarize.

Membrane depolarization forces the subsequent opening of voltage-gated L-type calcium channels, resulting in a sudden influx of calcium ions ( Ca^2+). This rise in intracellular calcium acts as the required signal, triggering the exocytosis of pre-formed insulin granules and achieving a high-magnitude, systemic release of the hormone.

This mechanism relies on the presence of functioning beta-cells and is notably glucose-dependent; its effectiveness is amplified in the presence of higher blood sugar. The resulting physiological effect is a rapid and transient surge of endogenous insulin, which facilitates the rapid regulation of circulating glucose.

Dosage and Administration Information

How Prandin is Used: Official Administration Guidelines

Prandin (Repaglinide) is administered exclusively via the oral route as an immediate-release tablet, available in 0.5 mg, 1 mg, and 2 mg strengths. The official usage protocol mandates a flexible, meal-dependent dosing schedule, requiring precise timing relative to food intake.


Administration Scope

Instruction Detail
Dosing Schedule The pre-prandial dose range is 0.5 mg to 4 mg. The maximum total daily dose is established as 16 mg.
Timing in Relation to Meals The medication must be taken pre-prandially (before meals). Instructions state the dose should be taken within 15 minutes of the meal, with an acceptable window extending up to 30 minutes before the meal.
Dose Titration Initial doses typically start at 0.5 mg to 2 mg before each main meal. The dosage may be adjusted, but a minimum of one week must elapse between dose changes to assess the treatment response.
Special Populations Conservative dosing, often starting at 0.5 mg, is required for patients with severe renal or hepatic impairment. Use in the pediatric population is not recommended.

Core Procedural Structure

The administration of Repaglinide is defined by a meal-dependent dosing principle. This principle mandates that the dose must be skipped if a meal is missed to avoid unintended effects, and conversely, a corresponding dose should be added if the patient consumes an extra main meal. This structure ensures the medication is only taken when blood glucose is expected to rise from food intake, aligning the drug's short action profile with the body's need for insulin secretion. Repaglinide is intended for long-term use as an adjunct to diet and exercise.

Recent Clinical Evidence

The Research Landscape for Repaglinide

This section summarizes the types of studies, such as Randomized Controlled Trials (RCTs) and meta-analyses, that form the official research evidence base for repaglinide, detailing what these studies were designed to measure. Research examined how this medication performs when used alone and when combined with other common diabetes medications, such as metformin. The evidence structure summarizes what research has explored in specific patient groups and identifies where data remain limited regarding long-term outcomes.


Evidence for Management of Type 2 Diabetes Mellitus

The primary research on repaglinide was studied for its use in Type 2 Diabetes Mellitus in adults. The primary research structure involves multiple clinical trials that included both placebo-controlled designs and active-controlled trials, which compared repaglinide against other established oral secretagogue medications like glibenclamide (glyburide), in both monotherapy and combination therapy settings. The populations observed included adults newly starting treatment and those previously treated with other oral anti-diabetic agents.

Outcomes Studied on Key Blood Sugar Markers

The research focused on core outcomes related to systemic or functional imbalance associated with high blood sugar. The long-term blood sugar marker, Glycosylated Hemoglobin ( HbA1c), was studied for changes over defined time intervals. Shorter-term studies also monitored changes in the blood sugar level before eating, known as Fasting Plasma Glucose (FPG).

Research also focused on how it data show patterns related to blood sugar spikes immediately following a meal, known as Postprandial Blood Glucose (PPBG). This profile is consistent with a mealtime regulating agent. Comparative trials studies monitored these blood markers. The findings describe patterns observed in the studies, including those comparing repaglinide to older agents on the HbA1c marker over intermediate durations. Trials also research describes the patient body weight changes observed during the study periods.


What Remains Uncertain in the Research Record

The evidence highlights what is known—and what is still uncertain—about this medication. Long-term effects are not fully established regarding protection against certain long-term, serious health issues. Specifically, official documentation states that dedicated clinical studies establishing evidence for the reduction of macrovascular risk (e.g., heart attack, stroke, or cardiovascular death) have not been conducted. Therefore, the evidence base does not provide insight into this critical area of long-term diabetes management.

Key Studies & References Repaglinide - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Prandin (FAQ)

Q: Is Prandin considered a type of insulin?

A: No, Prandin is not a type of insulin. It belongs to a class of drugs called meglitinide analogs that work by stimulating the release of your body's own insulin from the pancreas. This distinguishes it from exogenous (injected) insulin.


Q: How quickly does Prandin start working after taking it?

A: The official product information states that the release of insulin from the pancreas generally begins to increase within 30 minutes of taking a dose. This rapid action is consistent with its intended use to manage postprandial blood sugar spikes.


Q: Does Prandin cause weight gain?

A: The observed effects on body weight vary according to official study data. Studies reported an average weight gain of 3.3% in patients who were not previously treated with certain oral blood sugar-lowering agents. In studies of patients switched from previous treatments, the average change in body weight was not reported as a gain.


Q: Can Prandin be taken if a person has kidney problems?

A: Official documents state that the medication may be taken by patients with kidney problems. However, for those with severe renal impairment (a serious kidney condition), the official prescribing information recommends careful dose adjustment, typically starting with the lowest available dose.


Q: Is there a maximum number of meals per day I can take a dose of Prandin with?

A: The medication's dosing principle is meal-dependent and flexible, meaning the number of daily doses can be adjusted to match a patient's meal pattern. The official labeling states that the medication can be administered with two, three, or four meals per day, in line with the patient’s individual meal schedule.


Q: Are there any major food or drink restrictions while using Prandin?

A: Official regulatory information advises avoiding or limiting the consumption of alcohol, as it can significantly increase the risk of low blood sugar (hypoglycemia). Official information advises that significant alterations to grapefruit or grapefruit juice intake should be discussed with a healthcare provider due to a potential moderate drug interaction.


Q: Does alcohol consumption affect the way Prandin works?

A: Yes, according to official warnings, alcohol ingestion can increase the risk of developing low blood sugar (hypoglycemia). In some individuals, this low blood sugar may also be prolonged.


Q: Why is Prandin sometimes preferred over sulfonylurea drugs?

A: Official studies suggest that, due to its rapid-acting and short-duration profile, Repaglinide may be associated with a lower comparative risk of causing hypoglycemia than older secretagogues, such as sulfonylureas.


Q: Can Prandin be taken if I have a cold, flu, or an infection?

A: Conditions that cause increased stress on the body, such as fever, trauma, or infection, can cause a loss of blood sugar control. Regulatory guidance indicates that managing blood sugar during periods of acute stress, such as fever, trauma, or infection, may require temporary measures, including the discontinuation of this medication and a switch to insulin therapy.


Q: Is the brand name drug Prandin still available, or is only the generic repaglinide available?

A: The brand name drug Prandin is still regulated and available on the market. The key similarity is that the active pharmaceutical ingredient in both the brand name and the generic form is repaglinide.


Q: Can Prandin affect cholesterol levels or heart health?

A: Official product information states that dedicated clinical studies establishing conclusive evidence regarding the reduction of macrovascular complications (such as heart attack or stroke) with this medication have not been conducted.


Q: If I am sick or stressed, does it change how Prandin affects my blood sugar?

A: Yes, official documents state that conditions causing increased stress on the body, such as fever, infection, or surgery, may require changes to the overall diabetes treatment plan. These situations may result in a temporary loss of blood sugar control.


Q: Can Prandin affect my ability to drive or operate machinery?

A: The medication can affect alertness and coordination, particularly if blood sugar drops too low. Official warnings state that hypoglycemia can impair the concentration and reaction time required for activities like driving or operating machinery.


Q: Are there any reported interactions between Prandin and herbal products or vitamins?

A: While specific documented interactions with individual herbal products or vitamins are generally not listed in detail, official prescribing information strongly recommends disclosing all prescription and non-prescription medicines, vitamins, minerals, and herbal products to a healthcare provider for a thorough review of potential interactions.


Q: What should I know about switching from a different diabetes drug to Prandin?

A: According to official information, patients can be transferred directly from other oral blood sugar-lowering medicines to Repaglinide. However, regulatory documents indicate that no exact dosage relationship is established between this drug and others, and therefore, careful clinical monitoring is usually implemented during this transition.


Q: Does Prandin affect the risk of developing long-term diabetes complications?

A: Official product information states that dedicated clinical studies establishing conclusive evidence regarding the reduction of macrovascular complications (such as heart attack or stroke) with this medication have not been conducted.


Q: Do certain medications, like beta-blockers, make it harder to notice low blood sugar while on Prandin?

A: Yes, certain medications, such as beta-blockers, can make the symptoms of low blood sugar less obvious. This is because they may mask common signs of hypoglycemia, like rapid heartbeat or tremor.


Q: Do studies suggest a lower risk of hypoglycemia with Prandin compared to older drugs?

A: Studies indicate that due to its rapid onset and short duration of action, Repaglinide may be associated with a lower risk of causing hypoglycemia compared to older secretagogues, such as sulfonylureas.


Q: What are the official guidelines for stopping Prandin before major surgery?

A: Official warnings state that the stress from major surgery can cause a loss of blood sugar control. Regulatory guidance indicates that temporary discontinuation of the medication and replacement with insulin therapy may be implemented during the period surrounding the surgery.


Q: What other symptoms besides confusion and shaking are signs of severe low blood sugar with Prandin?

A: Official regulatory documents list other documented signs of low blood sugar. These symptoms can include headache, anxiety, intense hunger, dizziness, blurry vision, slurred speech, sweating, and potentially seizures.


Q: What is the difference between Prandin and its generic form, repaglinide?

A: The brand name drug Prandin is still available and regulated. The key similarity is that the active pharmaceutical ingredient in both the brand name and the generic form is repaglinide.


Q: Why are patients with diabetic ketoacidosis advised not to use Prandin?

A: The medication is formally contraindicated for conditions like diabetic ketoacidosis (DKA). This is because DKA is an acute metabolic condition caused by a severe deficiency of insulin, and regulatory guidance mandates that such conditions are treated with insulin, not an oral secretagogue.


Q: Does Prandin's effect wear off more quickly than insulin therapy?

A: Repaglinide is a rapid-acting medication characterized by a short half-life of about one hour. Its effect is rapid and short-acting, consistent with its intended use for regulating blood sugar during mealtimes.


Q: If I gain weight while on Prandin, is it guaranteed to be a side effect of the drug?

A: No single adverse event, including weight gain, is guaranteed to occur in any patient taking any medication. Clinical studies reported an average weight gain of 3.3% in patients who were not previously treated with certain oral agents, but this is not guaranteed for all individuals.


Q: Is there a common reason patients are usually taken off Prandin?

A: In clinical trials, the most common reasons leading to patient withdrawal were adverse reactions related to blood sugar control. These included episodes of both high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia), along with related symptoms.

How should Prandin be stored and disposed of?

How to Store and Dispose of Prandin?

Prandin (repaglinide) must be stored strictly according to regulatory requirements to ensure product stability. The required storage conditions are defined as Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted up to 30 C.

The medication must be stored in a tight, light-resistant container and the bottle must be kept tightly closed to protect the tablets from moisture and light. For safety, the container must have a child-resistant closure and must be kept out of the reach of children.

Disposal of any unused or expired Prandin must be handled in a manner that is consistent with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prandin found in:

A-Z Index: